NCT04497324View on ClinicalTrials.gov

PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

April 17, 2021

Study Completion Date

April 17, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Convalescent plasma

Administration of 1 to 2 units of convalescent plasma (200 ml to 250 ml, each), within 48 hours, plus standard of care.

Trial Locations (2)

15102

Hospital Cayetano Heredia, Lima

Unknown

Hospital Nacional Hipolito Unanue, Lima

All Listed Sponsors
lead

Universidad Peruana Cayetano Heredia

OTHER

NCT04497324 - PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 | Biotech Hunter | Biotech Hunter